Clinical trials: Epilepsy, Complex Partial
- Condition Epilepsy, Complex Partial
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Epilepsy, Complex Partial
Bioavailability, Safety, and Tolerability of BIS-001 ER
This study investigates the safety, tolerability, and pharmacokinetics of BIS-001 ER in healthy volunteers. Subjects will be dosed twice daily, with a dose escalation occurring every 2-3 days until a maximum dose of 5mg per day…
- Trial name
- NCT03156439
- Testing
- BIS-001 ER
- Where
- Australia
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Supernus Pharmaceuticals, Inc.